{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:50:43Z","timestamp":1794437443387,"version":"4.9.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>FLCr \u2265100 and BMPC \u226560% identify high-risk SMM, although with more modest median TTP and 2-year PD than previously published. Baseline immunoparesis, eMP, eHb, and edFLC can help identify an ultra-high-risk SMM cohort.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018016998","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T15:55:14Z","timestamp":1530028514000},"page":"1470-1479","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling"],"prefix":"10.1182","volume":"2","author":[{"given":"Vernon","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Leng","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Mazumdar","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"issue":"25","key":"2019111615562426800_B1","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111615562426800_B2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111615562426800_B3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrclinonc.2013.160","article-title":"Haematological cancer: treatment of smoldering multiple myeloma","volume":"10","author":"Rajkumar","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2019111615562426800_B4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111615562426800_B5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2019111615562426800_B6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Classifying ultra-high-risk smoldering myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2019111615562426800_B7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"S\u00f8rrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111615562426800_B8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Modeling the risk of progression in smoldering multiple myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2019111615562426800_B9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111615562426800_B10","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1002\/cncr.27657","article-title":"Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form","volume":"118","author":"Rago","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"2019111615562426800_B11","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"6","key":"2019111615562426800_B12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2019111615562426800_B13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111615562426800_B14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0049124101029003005","article-title":"A SAS procedure based on mixture models for estimating developmental trajectories","volume":"29","author":"Jones","year":"2001","journal-title":"Sociol Methods Res"},{"key":"2019111615562426800_B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1198\/016214507000000149","article-title":"Evaluating prediction rules for t-year survivors with censored regression models","volume":"102","author":"Uno","year":"2007","journal-title":"J Am Stat Assoc"},{"key":"2019111615562426800_B16","author":"Shtatland","year":"2005"},{"issue":"8","key":"2019111615562426800_B17","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"34","key":"2019111615562426800_B18","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111615562426800_B19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1515\/cclm-2015-0879","article-title":"Is accuracy of serum free light chain measurement achievable?","volume":"54","author":"Jacobs","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2019111615562426800_B20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1515\/cclm-2016-0268","article-title":"Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies","volume":"54","author":"Tate","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2019111615562426800_B21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.1992.tb04592.x","article-title":"Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma","volume":"82","author":"Terpstra","year":"1992","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111615562426800_B22","first-page":"1101","article-title":"CD138\/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathology","volume":"12","author":"Chilosi","year":"1999"},{"issue":"23","key":"2019111615562426800_B23","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2018024281","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/12\/1470\/881165\/advances016998.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/12\/1470\/881165\/advances016998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T20:56:33Z","timestamp":1573937793000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/12\/1470\/15906\/Risk-stratification-of-smoldering-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018016998","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2018024281","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}